TESTOLACTONE

US Previously Marketed

First approved in 1969

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H24O3
Molecular Weight	300.3921
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])CC[C@]4(C)OC(=O)CC[C@@]24[H]

InChI

InChIKey=BPEWUONYVDABNZ-DZBHQSCQSA-N

InChI=1S/C19H24O3/c1-18-9-7-13(20)11-12(18)3-4-14-15(18)8-10-19(2)16(14)5-6-17(21)22-19/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15+,16+,18+,19+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C19H24O3
Molecular Weight	300.3921
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/16118slr023_teslac_lbl.pdf

Testolactone (Teslac brand name) is an anti-cancer agent, which was used as adjunctive therapy in the palliative treatment of advanced or disseminated breast cancer. The mechanism of testolactone action is reported to be related to the inhibition of aromatase enzymatic activity. Testolactone is no longer available in the USA.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Aromatase 8 Target ID: P11511 Gene ID: 1588.0 Gene Symbol: CYP19A1 Target Organism: Homo sapiens (Human) Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/16118slr023_teslac_lbl.pdf	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Breast cancer 434 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/16118slr023_teslac_lbl.pdf	Palliative		Approved 8429	TESLAC Approved Use TESLAC (testolactone tablets, USP) is recommended as adjunctive therapy in the palliative treatment of advanced or disseminated breast cancer in postmenopausal women when hormonal therapy is indicated. It may also be used in women who were diagnosed as having had disseminated breast carcinoma when premenopausal, in whom ovarian function has been subsequently terminated. Launch Date 1.26144E10

C_max

Value	Dose	Co-administered	Analyte	Population
1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6643639/	500 mg 4 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TESTOLACTONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
3.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6643639/	500 mg 4 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TESTOLACTONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6643639/	500 mg 4 times / day steady-state, oral dose: 500 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TESTOLACTONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP19A1 60

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP19A1 60	inhibitor 3277 Sources: https://go.drugbank.com/drugs/DB00894	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:9460	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9460
ChemicalBook	CB4371689	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4371689
ZINC	ZINC000004081771	http://zinc15.docking.org/substances/ZINC000004081771
eMolecules	30151977	https://www.emolecules.com/cgi-bin/more?vid=30151977

PubMed

Title	Date	PubMed
A new hypothesis based on suicide substrate inhibitor studies for the mechanism of action of aromatase.	1982 Aug	7083195
Evidence of a treatable endocrinopathy in infertile men.	2001 Mar	11176482
Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome.	2002	12199354
McCune-Albright syndrome--the German experience.	2002	12199348
Feminizing Sertoli cell tumor associated with Peutz-Jeghers syndrome.	2002 Apr	12008693
Aromatase inhibitors for male infertility.	2002 Feb	11792932
[Androgen replacement therapy].	2002 Jun	12166151
Cyclic AMP and the reverse transformation reaction.	2002 Jun	12119272
Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone.	2003 Sep	14506617
Paediatric management of endocrine complications in McCune-Albright syndrome.	2005 Jan	15679067
Adult height after ketoconazole treatment in patients with familial male-limited precocious puberty.	2005 Jan	15522928
Dominant transmission of prepubertal gynecomastia due to serum estrone excess: hormonal, biochemical, and genetic analysis in a large kindred.	2005 Jan	15483104
Fate of novel Quasi reverse steroidal substrates by Aspergillus tamarii KITA: bypass of lactonisation and an exclusive role for the minor hydroxylation pathway.	2005 May 15	15904875
Structure-activity relationships of new A,D-ring modified steroids as aromatase inhibitors: design, synthesis, and biological activity evaluation.	2005 Oct 6	16190763
Heritability of testosterone levels in 12-year-old twins and its relation to pubertal development.	2006 Aug	16899163
Tamoxifen improved final height prediction in a girl with McCune-Albright syndrome: patient report and literature review.	2006 Jan	16509532
Use of aromatase inhibitors to increase final height.	2006 Jul 25	16766117
[Testotoxicosis].	2006 Jun 28	16817479
Synthesis of steroidal lactone by penicillium citreo-viride.	2006 Nov	16970967
Distinct metabolic handling of 3beta-hydroxy-17a-oxa-D-homo-5alpha-androstan-17-one by the filamentous fungus Aspergillus tamarii KITA: Evidence in support of steroid/hydroxylase binding hypothesis.	2007 Sep	17692565
Baeyer-Villiger oxidation of DHEA, pregnenolone, and androstenedione by Penicillium lilacinum AM111.	2008 Dec 22	18755205
Statistics and the prostate gland.	2008 Jun	18317483
Desmoid tumor of the supraclavicular region: a case report.	2009 Jun 22	19829936
Enhanced ERbeta immunoexpression and apoptosis in the germ cells of cimetidine-treated rats.	2009 Nov 18	19922658
Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promises.	2010	20652035
Management of the adult with congenital adrenal hyperplasia.	2010	20613954
An Evidence-Based Model of Multidisciplinary Care for Patients and Families Affected by Classical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.	2010	20339513
3β,11α-Dihy-droxy-17a-oxa-d-homoandrost-5-en-17-one.	2010 Jul 14	21588317

Patents

Sample Use Guides

In Vivo Use Guide

The recommended oral dose is 250 mg qid.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:09:05 UTC 2023` Edited by `admin` on `Fri Dec 15 15:09:05 UTC 2023`
Record UNII	6J9BLA949Q
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TESTOLACTONE

Official Name

English

TESTOLACTONE [HSDB]

Common Name

English

TESTOLACTONE [VANDF]

Common Name

English

NSC-23759

Code

English

TEOLIT

Brand Name

English

TESTOLACTONE [USAN]

Common Name

English

TESTOLACTONE [MI]

Common Name

English

TESTOLACTONE CIII

Common Name

English

TESTOLACTONE CIII [USP-RS]

Common Name

English

testolactone [INN]

Common Name

English

TESLAC

Brand Name

English

TESTOLACTONE [ORANGE BOOK]

Common Name

English

Testolactone [WHO-DD]

Common Name

English

TESTOLACTONE [USP IMPURITY]

Common Name

English

TESTOLACTONE [USP-RS]

Common Name

English

SQ-9538

Code

English

SQ 9538

Code

English

Classification Tree Code System Code

NDF-RT

N0000175563